Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 1/20 | 0.44 |
| ▸ | AGBL2 | Q5U5Z8 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.34 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20031269 | 0.80 | GAA (0.41) | FBP1AGBL2KDM4ENOTUMGABRR1 | |
| SCHEMBL2305553 | 0.78 | FBP1 (0.42) | FBP1KDM4EALDH1A1NPC1PKM | |
| SCHEMBL13765709 | 0.76 | KDM4E (0.57) | AGBL2KDM4EALDH1A1GABRR1RAB9A | |
| SCHEMBL24423863 | 0.74 | FBP1 (0.39) | FBP1ALDH1A1NPC1PKMRAB9A | |
| SCHEMBL621837 | 0.74 | FBP1 (0.39) | FBP1ALDH1A1NPC1MAPT | |
| SCHEMBL569207 | 0.73 | FBP1 (0.55) | FBP1ALDH1A1NPC1PKMRAB9A | |
| SCHEMBL568661 | 0.69 | FBP1 (0.55) | FBP1ALDH1A1NPC1PKMRAB9A | |
| SCHEMBL15650510 | 0.68 | FBP1 (0.54) | FBP1ALDH1A1NPC1PKMRAB9A | |
| SCHEMBL15639468 | 0.68 | KDM4E (0.39) | AGBL2KDM4EGABRR1MAPTSMN1; SMN2 | |
| SCHEMBL24424625 | 0.67 | FBP1 (0.72) | FBP1KDM4EALDH1A1NPC1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233850-B1 | HYDROXY CONTAINING FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2019-04-03 | — | — | EP | disclosed |
| WO-2018059314-A1 | AZABICYCLE DERIVATIVES AND PREPARATION METHOD AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2018-04-05 | — | — | WO | disclosed |
| US-9751874-B2 | Hydroxy containing FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| WO-2016096115-A1 | HYDROXY CONTAINING FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| US-20160176861-A1 | HYDROXY CONTAINING FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176861-A1 | HYDROXY CONTAINING FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H3, NR1H2 | FBP1 415/4885AGBL2 3227/4885KDM4E 3050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.